Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828425 | 0.81 | AKR1C3 (0.54) | CYP1A2LMNA | |
| SCHEMBL28849408 | 0.75 | UGT2B7 (0.50) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3579124 | 0.74 | UGT2B7 (0.53) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6410479 | 0.73 | SLC6A2 (0.46) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27517796 | 0.73 | LTA4H (0.52) | RAB9AMEN1KMT2A | |
| SCHEMBL17585046 | 0.72 | UGT2B7 (0.52) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9657913 | 0.71 | L3MBTL1 (0.69) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17585039 | 0.70 | TDP1 (0.62) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7144687 | 0.70 | NPC1 (0.52) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27512232 | 0.69 | UGT2B7 (0.62) | CYP2D6UGT2B7CYP1A2MMP9ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861417-B2 | Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040014973-A1 | Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines | SMITHKLINE BEECHAM CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1126852-B1 | PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6548503-B1 | 2-(4-Fluorophenyl)-3-(pyridin-4-yl)pyrazine for example; inhibits p38 kinases; cytokine suppressive anti-inflammatory drugs | SMITHKLINE BEECHAM CORPORATION | 2003-04-15 | — | — | US | disclosed |
| EP-1126852-A4 | PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES | SMITHKLINE BEECHAM CORP (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1126852-A1 | PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES | SmithKline Beecham Corporation (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025791-A1 | PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014973-A1 | Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines | TK2, TYMP, MPL | CYP3A4 404/4885CYP2D6 900/4885SLC6A2 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.